The China Mail - The scientist rewriting DNA, and the future of medicine

USD -
AED 3.673035
AFN 72.04561
ALL 90.426454
AMD 393.432155
ANG 1.790208
AOA 916.000197
ARS 1080.807695
AUD 1.67189
AWG 1.8
AZN 1.735183
BAM 1.784082
BBD 2.031653
BDT 122.253136
BGN 1.784082
BHD 0.379293
BIF 2990.649943
BMD 1
BND 1.345222
BOB 6.952794
BRL 5.8439
BSD 1.006157
BTN 85.842645
BWP 14.014139
BYN 3.292862
BYR 19600
BZD 2.021163
CAD 1.425189
CDF 2873.000047
CHF 0.852465
CLF 0.0249
CLP 955.540159
CNY 7.28155
CNH 7.3093
COP 4181.71
CRC 509.007982
CUC 1
CUP 26.5
CVE 100.583808
CZK 23.02904
DJF 179.18358
DKK 6.80759
DOP 63.5439
DZD 133.249715
EGP 50.896204
ERN 15
ETB 132.622212
EUR 0.91216
FJD 2.314902
FKP 0.774531
GBP 0.77497
GEL 2.749664
GGP 0.774531
GHS 15.453612
GIP 0.774531
GMD 71.461814
GNF 8669.802009
GTQ 7.716149
GYD 210.168965
HKD 7.773075
HNL 25.661585
HRK 6.860297
HTG 132.890785
HUF 370.408231
IDR 16571.70415
ILS 3.743625
IMP 0.774531
INR 85.511582
IQD 1310.012402
IRR 42003.703205
ISK 132.195716
JEP 0.774531
JMD 157.257424
JOD 0.70897
JPY 145.487015
KES 129.458675
KGS 86.768703
KHR 3997.413216
KMF 448.929755
KPW 900.000008
KRW 1460.898192
KWD 0.308471
KYD 0.820003
KZT 508.402314
LAK 21614.631408
LBP 90013.256713
LKR 295.427831
LRD 199.87708
LSL 19.106655
LTL 2.95274
LVL 0.60489
LYD 4.833883
MAD 9.545567
MDL 17.570983
MGA 4650.986319
MKD 56.074316
MMK 2099.341751
MNT 3508.091945
MOP 8.007849
MRU 39.895403
MUR 44.572925
MVR 15.45336
MWK 1733.408678
MXN 20.67145
MYR 4.436766
MZN 63.569588
NAD 19.106655
NGN 1529.710967
NIO 36.648194
NOK 10.835012
NPR 136.882666
NZD 1.806081
OMR 0.384998
PAB 1
PEN 3.678016
PGK 4.09838
PHP 57.406582
PKR 280.349118
PLN 3.894301
PYG 8051.312968
QAR 3.640096
RON 4.543573
RSD 106.910099
RUB 84.408708
RWF 1410.456645
SAR 3.750143
SBD 8.499799
SCR 14.808814
SDG 599.188018
SEK 10.04327
SGD 1.345976
SHP 0.785843
SLE 22.749903
SLL 20969.501083
SOS 569.536574
SRD 36.504913
STD 20697.981008
SVC 8.749853
SYP 13001.836564
SZL 19.106655
THB 34.316411
TJS 10.845699
TMT 3.49741
TND 3.056623
TOP 2.404411
TRY 38.003595
TTD 6.731512
TWD 33.207637
TZS 2665.220063
UAH 41.465337
UGX 3656.581024
UYU 42.25152
UZS 12934.705202
VES 70.624618
VND 25785.448419
VUV 122.117516
WST 2.799576
XAF 598.573006
XAG 0.034996
XAU 0.000335
XCD 2.700132
XDR 0.746748
XOF 598.573006
XPF 108.892442
YER 245.542765
ZAR 19.3363
ZMK 9001.205782
ZMW 27.907397
ZWL 321.999592
  • SCS

    -0.0600

    10.68

    -0.56%

  • RBGPF

    69.0200

    69.02

    +100%

  • VOD

    -0.8700

    8.5

    -10.24%

  • GSK

    -2.4800

    36.53

    -6.79%

  • RYCEF

    -1.5500

    8.25

    -18.79%

  • CMSD

    0.1600

    22.83

    +0.7%

  • CMSC

    0.0300

    22.29

    +0.13%

  • NGG

    -3.4600

    65.93

    -5.25%

  • BTI

    -2.0600

    39.86

    -5.17%

  • RIO

    -3.7600

    54.67

    -6.88%

  • JRI

    -0.8600

    11.96

    -7.19%

  • RELX

    -3.2800

    48.16

    -6.81%

  • BCE

    0.0500

    22.71

    +0.22%

  • BCC

    0.8100

    95.44

    +0.85%

  • AZN

    -5.4600

    68.46

    -7.98%

  • BP

    -2.9600

    28.38

    -10.43%

The scientist rewriting DNA, and the future of medicine
The scientist rewriting DNA, and the future of medicine / Photo: © Broad Institute of Harvard and MIT,/AFP

The scientist rewriting DNA, and the future of medicine

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.

Text size:

A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.

He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.

He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.

"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.

- Correcting the code -

DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.

Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.

It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.

"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.

That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.

Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.

These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.

In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.

While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.

"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.

- Cystic fibrosis hope -

Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.

About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.

To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.

If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.

Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."

Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.

Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.

"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."

This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).

"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."

P.Deng--ThChM